Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,547 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.
Rouphael NG, Paine M, Mosley R, Henry S, McAllister DV, Kalluri H, Pewin W, Frew PM, Yu T, Thornburg NJ, Kabbani S, Lai L, Vassilieva EV, Skountzou I, Compans RW, Mulligan MJ, Prausnitz MR; TIV-MNP 2015 Study Group. Rouphael NG, et al. Among authors: henry s. Lancet. 2017 Aug 12;390(10095):649-658. doi: 10.1016/S0140-6736(17)30575-5. Epub 2017 Jun 27. Lancet. 2017. PMID: 28666680 Free PMC article. Clinical Trial.
Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial.
Rouphael NG, Lai L, Tandon S, McCullough MP, Kong Y, Kabbani S, Natrajan MS, Xu Y, Zhu Y, Wang D, O'Shea J, Sherman A, Yu T, Henry S, McAllister D, Stadlbauer D, Khurana S, Golding H, Krammer F, Mulligan MJ, Prausnitz MR. Rouphael NG, et al. Among authors: henry s. NPJ Vaccines. 2021 Jul 14;6(1):89. doi: 10.1038/s41541-021-00353-0. NPJ Vaccines. 2021. PMID: 34262052 Free PMC article.
Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].
Adigweme I, Akpalu E, Yisa M, Donkor S, Jarju LB, Danso B, Mendy A, Jeffries D, Njie A, Bruce A, Royals M, Goodson JL, Prausnitz MR, McAllister D, Rota PA, Henry S, Clarke E. Adigweme I, et al. Among authors: henry s. Trials. 2022 Sep 14;23(1):775. doi: 10.1186/s13063-022-06493-5. Trials. 2022. PMID: 36104719 Free PMC article.
Assessing the risk of a clinically significant infection from a Microneedle Array Patch (MAP) product.
Dul M, Alali M, Ameri M, Burke MD, Craig CM, Creelman BP, Dick L, Donnelly RF, Eakins MN, Frivold C, Forster AH, Gilbert PA, Henke S, Henry S, Hunt D, Lewis H, Maibach HI, Mistilis JJ, Park JH, Prausnitz MR, Robinson DK, Hernandez CAR, Ross C, Shin J, Speaker TJ, Taylor KM, Zehrung D, Birchall JC, Jarrahian C, Coulman SA. Dul M, et al. Among authors: henry s. J Control Release. 2023 Sep;361:236-245. doi: 10.1016/j.jconrel.2023.07.001. Epub 2023 Aug 8. J Control Release. 2023. PMID: 37437849 Free article.
A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
Adigweme I, Yisa M, Ooko M, Akpalu E, Bruce A, Donkor S, Jarju LB, Danso B, Mendy A, Jeffries D, Segonds-Pichon A, Njie A, Crooke S, El-Badry E, Johnstone H, Royals M, Goodson JL, Prausnitz MR, McAllister DV, Rota PA, Henry S, Clarke E. Adigweme I, et al. Among authors: henry s. Lancet. 2024 May 11;403(10439):1879-1892. doi: 10.1016/S0140-6736(24)00532-4. Epub 2024 Apr 29. Lancet. 2024. PMID: 38697170 Free PMC article. Clinical Trial.
White paper: Understanding, informing and defining the regulatory science of microneedle-based dosage forms that are applied to the skin.
Dul M, Alali M, Ameri M, Burke MD, Creelman BP, Dick L, Donnelly RF, Eakins MN, Frivold C, Forster AH, Gilbert PA, Henke S, Henry S, Hunt D, Lewis H, Mistilis JJ, Park JH, Prausnitz MR, Robinson DK, Hernandez CAR, Shin J, Speaker TJ, Strasinger C, Taylor KMG, Zehrung D, Birchall JC, Jarrahian C, Coulman SA. Dul M, et al. Among authors: henry s. J Control Release. 2024 Nov 25:S0168-3659(24)00815-0. doi: 10.1016/j.jconrel.2024.11.056. Online ahead of print. J Control Release. 2024. PMID: 39603537
1,547 results